Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [982]
News [2877]
Articles [137]
Editorials [3]
Conferences [93]
elearning [27]

Caring for lung cancer patients

Dr Mark Doherty - Princess Margaret Hospital, Toronto, Canada
Caring for lung cancer patients ( Dr Mark Doherty - Princess Margaret Hospital, Toronto, Canada )
10 Oct 2016

Highlights of ESMO 2016

Dr Andrés Cervantes - ESMO 2016 Scientific Chair
Highlights of ESMO 2016 ( Dr Andrés Cervantes - ESMO 2016 Scientific Chair )
10 Oct 2016

Advances for NSCLC in review

Dr Stefan Zimmermann - Hôpital Fribourgeois, Fribourg, Switzerland
Advances for NSCLC in review ( Dr Stefan Zimmermann - Hôpital Fribourgeois, Fribourg, Switzerland )
9 Oct 2016

Ceritinib following crizotinib relapse for ALK positive NSCLC

Dr Giorgio Scagliotti - University of Turin, Turin, Italy
Ceritinib following crizotinib relapse for ALK positive NSCLC ( Dr Giorgio Scagliotti - University of Turin, Turin, Italy )
9 Oct 2016

Atezolizumab v docetaxel for NSCLC: results from the OAK trial

Dr Fabrice Barlesi - Hôpital Nord, Marseille, France
Atezolizumab v docetaxel for NSCLC: results from the OAK trial ( Dr Fabrice Barlesi - Hôpital Nord, Marseille, France )
9 Oct 2016

Significant survival gains with atezolizumab for NSCLC

Dr Fabrice Barlesi - Hôpital Nord, Marseille, France
Significant survival gains with atezolizumab for NSCLC ( Dr Fabrice Barlesi - Hôpital Nord, Marseille, France )
9 Oct 2016

Pembrolizumab new option for firstline treatment of advanced lung cancer with high PDL-1 expression

Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany
Pembrolizumab new option for firstline treatment of advanced lung cancer with high PDL-1 expression ( Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany )
9 Oct 2016

Pembrolizumab plus chemo as firstline therapy for NSCLC

Dr Corey Langer - University of Pennsylvania, Philadelphia, USA
Pembrolizumab plus chemo as firstline therapy for NSCLC ( Dr Corey Langer - University of Pennsylvania, Philadelphia, USA )
9 Oct 2016

ASCEND-5: Ceritinib for ALK positive NSCLC previously treated with crizotinib

Dr Giorgio Scagliotti - University of Turin, Turin, Italy
ASCEND-5: Ceritinib for ALK positive NSCLC previously treated with crizotinib ( Dr Giorgio Scagliotti - University of Turin, Turin, Italy )
9 Oct 2016

Pembrolizumab 'should be first line treatment' for high PD1 expressing NSCLC patients

Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany
Pembrolizumab 'should be first line treatment' for high PD1 expressing NSCLC patients ( Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany )
9 Oct 2016

Firstline pembrolizumab plus chemo improves NSCLC outcomes

Dr Corey Langer - University of Pennsylvania, Philadelphia, USA
Firstline pembrolizumab plus chemo improves NSCLC outcomes ( Dr Corey Langer - University of Pennsylvania, Philadelphia, USA )
9 Oct 2016

Immunotherapy and treatment advances in small cell lung cancer

Prof Dean Fennell - University of Leicester, Leicester, UK
Immunotherapy and treatment advances in small cell lung cancer ( Prof Dean Fennell - University of Leicester, Leicester, UK )
6 Oct 2016

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation